Key result
Database analysis links nivolumab use in thymoma patients to adjudicated cases of myocarditis.
Why the study?
Myocarditis is associated with thymoma and is also an uncommon, potentially lethal immune-related adverse event with immune checkpoint inhibitors; investigators hypothesized it would be more common in ICI-treated patients with versus without thymoma.
Does a history of thymoma increase the risk of myocarditis in patients treated with immune checkpoint inhibitors?
Observational
Does a history of thymoma increase the risk of myocarditis in patients treated with immune checkpoint inhibitors?
This study investigates whether patients with a history of thymoma are at an increased risk of developing potentially lethal myocarditis when treated with immune checkpoint inhibitors.
Thymoma history may heighten myocarditis risk with ICIs; leaves open quantitative confirmation in prospective cohorts.
Myocarditis Associated With Immune Checkpoint Inhibitors in Patients With ThymomaMyocarditis is associated with thymoma, and is also an uncommon, but potentially lethal, immunerelated adverse event (irAE) reported with the use of immune checkpoint inhibitors (ICIs). 1,2 hypothesized that among patients treated with ICIs, myocarditis would be more common in those with, as compared to those without, a history or previous treatment for thymoma.A comprehensive search of the Bristol Myers Squibb (BMS) internal databases-clinical trial database and the BMS safety database (including clinical trial and spontaneous postmarketing reports)-was conducted on March 10, 2022, for irAEs in patients with a history or indication for treatment of thymoma or thymic cancer who received nivolumab either as monotherapy or in combination with ipilimumab or relatlimab.All cases reporting myocarditis from both databases were adjudicated by 3 physicians with expertise in ICI therapy and myocarditis.
No takes yet. Share an insight, caveat, or question.
Cooper et al. (2023) conducted an observational in Thymoma or thymic cancer. Nivolumab (monotherapy or in combination with ipilimumab or relatlimab) was evaluated on Myocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: